ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Active ETF
    • Alternatives
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Disruptive Technology
    • Dividend
    • Dual Impact
    • Emerging Markets
    • Energy Infrastructure
    • ESG
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Fixed Income
    • Free Cash Flow
    • Future ETFs
    • Global Diversification
    • Gold & Silver Investing
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Market Insights
    • Megatrends
    • Modern Alpha
    • Multi-Asset
    • Night Effect
    • Portfolio Strategies
    • Retirement Income
    • Richard Bernstein Advisors
    • Tax Efficient Income
    • Thematic Investing
    • Volatility Resource
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
    • ETF Data for Journalists
    • ETF Nerds
  • Research
    • First Bitcoin ETF
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Multimedia
    • ETF 360 Video Series
    • ETF Trends on Videos
    • ETF Trends on Podcasts
    • ETF Prime Podcast
  • Company
    • About Us
    • Swag Store
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Nasdaq Portfolio Solutions Channel
  2. Pfizer’s COVID-19 Pill is 89% Effective
Nasdaq Portfolio Solutions Channel
Share

Pfizer’s COVID-19 Pill is 89% Effective

Karrie GordonNov 05, 2021
2021-11-05

Pfizer Inc. has announced that preliminary findings from an experimental pill used to treat those diagnosed with COVID-19 was extremely effective at preventing death and hospitalization, reports the Wall Street Journal.

For those with a mild to moderate COVID-19 infection that took the pill, Paxlovid, within three days of diagnosis, there was an 89% reduction in hospitalization or death, and the pill is considered generally safe and was tolerated well by those that took it in the study. It has shown to be effective against variants such as Delta, which has ravaged global populations and economies in recent months.

Pfizer will be meeting with the FDA this month to request authorization of the pill, and if approved, it could start rolling out by the end of the year. They have already begun the process for regulatory reviews, submitting information on the drug manufacture and other requirements to the FDA.

“It’s stunning data,” Dr. Mikael Dolsten, Pfizer’s chief scientific officer, said in an interview. ”I feel very optimistic on a day like this. For everyone living in this pandemic, a new light of hope has turned on.”

The approval by the FDA would increase Pfizer’s presence and role in the COVID-19 response globally; its shot, created with BioNTech SE, is the preferred shot worldwide, and Pfizer just raised its estimates for vaccine sales to $36 billion this year.

USMC Captures the Growth of Industry Movers Like Pfizer

Pfizer continues to grow with the recent emergency approval of the COVID-19 vaccine for children ages 5–11. The Principal U.S. Mega-Cap ETF (USMC A) invests in major movers such as Pfizer and offers exposure to the biggest companies within their industries.


Content continues below advertisement

Principal US Mega-Cap ETF

USMC tracks the Nasdaq US Mega Cap Select Leaders Index, a modified equal-weighted index.

The smart beta index takes the top half of securities on the Nasdaq US 500 Large Cap Index and divides the top 10% of companies by market value from the bottom 90%. The top 10% of companies are weighted by market value, while the bottom 90% are equal-weighted and tilted toward those firms with less volatility.

The index is rebalanced semi-annually, though securities that become ineligible for the index between balancing periods are removed without being replaced.

As a smart beta ETF, USMC’s benchmark seeks to provide optimal outcomes on downturns and to capitalize on surges while minimizing exposure to volatility.

USMC is currently comprised of 44 holdings. Pfizer (PFE) is carried at a 1.20% weighting.

The ETF carries an expense ratio of 0.12%.

For more news, information, and strategy, visit the Nasdaq Portfolio Solutions Channel.

Loading Articles...
Help & Info
  • Contact Us
Tools
  • ETF Screener
  • ETF Analyzer
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Performance Visualizer
  • ETF Database Model Portfolios
  • ETF Database Realtime Ratings
  • ETF Database Pro
More Tools
  • ETF Launch Center
  • Financial Advisor & RIA Center
  • ETF Database RSS Feed
Explore ETFs
  • ETF News
  • ETF Picks of the Month
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Best ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Legal
  • Terms of Use and Privacy Policy
  • © 2023 VettaFi LLC. All rights reserved.
Follow ETF Database
Follow ETF Database

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X